RxDoctor Payments Data

Rajwinder Kaur

Family · Sacramento, CANPI 1083265565

Payments from drug & device makers

$6,345in general payments, 2019–2025

Across 295 payments — averaging $21.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$696
  • AstraZeneca$649
  • Amgen$514
  • Boehringer Ingelheim$464
  • United Therapeutics Corporation$219
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$6,345100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,345 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$38,980
Medicare patients
295
Services billed
454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter160$129,998
TezspireTezepelumab-Ekko15$66,914
Spiriva RespimatTiotropium Bromide58$34,667
Breztri AerosphereBudesonide/Glycopyr/Formoterol46$32,900
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr45$28,620
Breo ElliptaFluticasone/Vilanterol56$26,171
Stiolto RespimatTiotropium Br/Olodaterol Hcl28$18,906
EliquisApixaban21$13,442
SymbicortBudesonide/Formoterol Fumarate40$10,693
Incruse ElliptaUmeclidinium Bromide15$8,626
Albuterol Sulfate HfaAlbuterol Sulfate311$7,131
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate26$5,936
Fluticasone-SalmeterolFluticasone Propion/Salmeterol33$5,087
BreynaBudesonide/Formoterol Fumarate45$4,476
Fluticasone Propionate HfaFluticasone Propionate23$4,466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$696$193,415276 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$649$110,506101 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$464$53,57486 claims
PfizerEliquis$40$13,44221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →